Commercialization
-
Getty Images
The FDA’s shame game
The agency is becoming more open about its criticisms of pharma companies and leaders, raising new privacy concerns in the industry.
By Kelly Bilodeau • March 30, 2026 -
Getty Images
Can Ocugen succeed where other gene therapy makers have struggled?
The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization challenges that have dogged the space.
By Meagan Parrish • March 27, 2026 -
Permission granted by Gilead Sciences
Deep DiveGilead could potentially end HIV. But will it be able to?
After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.
By Meagan Parrish • March 20, 2026 -
Courtesy of Novo Nordisk
Novo regained weight loss footing in the pill arena — but Lilly is coming
Eli Lilly has run away with the GLP-1 market. But can Novo Nordisk maintain pole position in the oral space?
By Alivia Kaylor • March 13, 2026 -
Permission granted by Bayer
Bayer sets the stage for a pharma comeback
The pharma giant’s drug sales haven’t wowed in recent years. But that could soon change.
By Meagan Parrish • Feb. 6, 2026 -
Andrew Harnik via Getty Images
Why TrumpRx is stumbling before it gets off the ground
Concerns about potential kickbacks, costs and conflicts have triggered calls for oversight.
By Kelly Bilodeau • Feb. 4, 2026 -
Getty Images
Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
The GLP-1 giants are the first to try out this new model, but more companies may follow.
By Kelly Bilodeau • Jan. 14, 2026 -
Getty Images
Hemophilia gene therapies are struggling on the market, even as innovation soars
The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.
By Kelly Bilodeau • Dec. 3, 2025 -
Courtesy of Madrigal
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.
By Kelly Bilodeau • Nov. 19, 2025 -
Getty Images
Is that pharma influencer human or AI?
Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.
By Meagan Parrish • Nov. 14, 2025 -
Permission granted by Geron
Q&A // First 90 DaysAfter a lackluster first drug launch, a new CEO is finding Geron’s commercial footing
Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.
By Alexandra Pecci • Nov. 12, 2025 -
Permission granted by Sarepta Therapeutics
Drugs are winning approval even when trials fail — but should they?
About 10% of FDA-approved drugs in recent years have won clearance despite a trial failure, raising safety and ethical concerns.
By Kelly Bilodeau • Nov. 12, 2025 -
Courtesy of Eisai
Alzheimer’s drug uptake hits its stride after a sluggish start
Sales of Eli Lilly’s Kisunla, and Eisai and Biogen’s Leqembi are on the rise as doctors grow more confident and new dosing options ease treatment hurdles.
By Kelly Bilodeau • Nov. 10, 2025 -
Courtesy of Merck
Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?
This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.
By Michael Gibney • Oct. 2, 2025 -
Getty Images
Is pharma’s IRA pricing battle running out of steam?
Despite recent court losses, the legal tides could still turn in the industry’s favor.
By Meagan Parrish • Sept. 26, 2025 -
Getty Images
A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant
Newcomers looking for a way into the obesity space are developing unique methods to snag market share.
By Amy Baxter • Aug. 27, 2025 -
Getty Images
The biggest Big Pharma losers in the first half of 2025
What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.
By Michael Gibney • Aug. 21, 2025 -
Andrew Harnik via Getty Images
MAHA leaders may take aim at pharma DTC advertising
RFK Jr. has his sights set on increasing advertising enforcement against pharmas, but may not come down as hard on the industry as previously thought.
By Amy Baxter • Aug. 20, 2025 -
Mario Tama / Getty via Getty Images
Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market
Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole.
By Amy Baxter • Aug. 18, 2025 -
Scott Olson via Getty Images
3 ways the GLP-1 market has changed shape this year
Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.
By Amy Baxter • Aug. 12, 2025 -
Getty Images
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
By Meagan Parrish • Aug. 8, 2025 -
Permission granted by Roche
Roche pushes ahead with late-comer strategy in obesity
The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.
By Amy Baxter • July 30, 2025 -
Getty Images
Novartis’ Zolgensma sales fall again as gene therapy market woes persist
Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?
By Michael Gibney • July 22, 2025 -
Mario Tama via Getty Images
3 major patent losses this year — and a key strategy to fill the gaps
Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.
By Kelly Bilodeau • July 21, 2025 -
Getty Images
Q&ANeed a DTC platform? Here’s how one company built its own.
Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med.
By Amy Baxter • July 14, 2025
